Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price objective lifted by JPMorgan Chase & Co. from $900.00 to $950.00 in a research report sent to investors on Friday morning, The Fly reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. A number of other research firms also recently […]